Goldman Sachs’ leading pharmaceutical expert is leaving the bank.

Jami Rubin stated in an e-mail acquired by Organisation Expert that she’s preparing to end up being a lender and tactical consultant.

A spokesperson from Goldman Sachs verified the contents of the e-mail.

Rubin’s been an expert given that the early 1990 s and has actually notoriously pushed significant pharmaceutical business on their merger and acquisition strategies. She signed up with Goldman Sachs in 2008 after operating at Morgan Stanley and ended up being a partner in2012

.

At Goldman Sachs, she’s covered business consisting of Pfizer, Merck, Bristol-Myers, Johnson & Johnson and Allergan. For many years, she consistently asked Pfizer about its strategy to separate and spin off a few of its services, a refrain that’s rollovered into other huge pharmaceutical business. In 2016, Fortune called Rubin the “Corporation Killer.”

“I am going to miss out on playing the “activist” expert and asking difficult concerns,” Rubin stated in the e-mail.